Weekly Analysts’ Ratings Changes for Neuronetics (STIM)

Several analysts have recently updated their ratings and price targets for Neuronetics (NASDAQ: STIM):

• 9/17/2026 – Neuronetics had its “buy” rating reaffirmed by BTIG Research. They now have a $6.00 price target on the stock.
• 9/14/2026 – Neuronetics had its “sell (e+)” rating reaffirmed by Weiss Ratings.
• 9/11/2026 – Neuronetics is now covered by B Riley. They set a “buy” rating on the stock.
• 9/11/2026 – Neuronetics is now covered by B. Riley Financial, Inc.. They set a “buy” rating and a $5.00 price target on the stock.
• 9/9/2026 – Neuronetics had its “buy” rating reaffirmed by BTIG Research. They now have a $6.00 price target on the stock.
• 8/11/2026 – Neuronetics had its price target raised by BTIG Research from $5.00 to $6.00. They now have a “buy” rating on the stock.

Insiders Place Their Bets

In other news, major shareholder Jorey Chernett acquired 14,000 shares of the company’s stock in a transaction dated Friday, August 14th. The shares were bought at an average price of $3.16 per share, for a total transaction of $44,240.00. Following the completion of the purchase, the insider directly owned 10,602,988 shares of the company’s stock, valued at approximately $33,505,442.08. This trade represents a 0.13% increase in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 8.40% of the stock is currently owned by corporate insiders.

Neuronetics, Inc is a medical technology company focused on developing and commercializing noninvasive treatments for patients with psychiatric and neurological disorders. The company’s flagship product is NeuroStar Advanced Therapy, a transcranial magnetic stimulation (TMS) system designed to deliver personalized, outpatient treatment for major depressive disorder and obsessive-compulsive disorder.

NeuroStar systems use magnetic pulses to stimulate targeted areas of the brain without surgery or anesthesia.